NAGE
Niagen Bioscience Inc
$3.49
+0.12
(+3.56%)
Mkt Cap
271.19M
Volume
630,824
52W Range
3.18-12.19
Sector
Healthcare
Beta
2.08
EPS (TTM)
0.23
P/E Ratio
14.53
Revenue (TTM)
130.42M
Rev Growth (5Y)
+16.9%
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
What we estimate one share is worth
$6.26
Undervalued
strong signal
45.6% below fair value
Modeled from cash flows & growth.
AlphaQuality · Grade · Gated
How strong & durable the business is
F
Platform & Compounding FCF
30.0 / 100 pillar composite (overridden)
A platform business that compounds free cash flow — graded A–F vs. similar companies.
Company Description
Niagen Bioscience Inc operates as a biotechnology enterprise with a core focus on promoting healthy aging. This company is also renowned for its pioneering research into nicotinamide adenine dinucleotide.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 129.42M | 99.60M | 83.57M | 72.05M | 67.45M | 59.26M | 46.29M | 31.56M | 21.20M | 21.66M | 17.88M | 15.31M |
| Net Income | 17.38M | 8.55M | (4.94M) | (16.54M) | (27.13M) | (19.93M) | (32.15M) | (33.32M) | (11.38M) | (2.93M) | (2.77M) | (5.39M) |
| EPS | 0.22 | 0.10 | -0.07 | -0.24 | -0.40 | -0.33 | -0.56 | -0.61 | -0.26 | -0.08 | -0.08 | -0.15 |
| Free Cash Flow | 13.14M | 11.95M | 6.97M | (15.43M) | (24.57M) | (10.74M) | (21.19M) | (22.36M) | (11.15M) | (4.66M) | (2.76M) | (2.83M) |
| FCF / Share | 0.17 | 0.14 | 0.10 | -0.22 | -0.37 | -0.18 | -0.37 | -0.41 | -0.25 | -0.12 | -0.08 | -0.08 |
| Operating CF | 13.44M | 12.11M | 7.12M | (15.10M) | (24.16M) | (10.60M) | (20.44M) | (20.91M) | (9.80M) | (2.94M) | (2.11M) | (2.58M) |
| Total Assets | 106.41M | 68.28M | 54.96M | 54.06M | 57.84M | 38.36M | 40.25M | 42.23M | 62.72M | 19.75M | 18.75M | 11.52M |
| Total Debt | 2.82M | 2.65M | 3.28M | 4.26M | 4.70M | 1.64M | 1.72M | 310,000 | 506,000 | 599,050 | 5.54M | 2.77M |
| Cash & Equiv | 64.79M | 44.51M | 27.17M | 20.29M | 28.02M | 16.50M | 18.61M | 22.42M | 45.39M | 1.64M | 5.55M | 3.96M |
| Book Value | 76.53M | 46.09M | 28.46M | 28.67M | 31.73M | 16.42M | 20.45M | 27.18M | 53.83M | 9.97M | 5.27M | 4.00M |
| Return on Equity | 0.23 | 0.19 | -0.17 | -0.58 | -0.86 | -1.21 | -1.57 | -1.23 | -0.21 | -0.29 | -0.53 | -1.35 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 31.47M | 33.84M | 33.99M | 31.12M | 30.48M | 29.12M | 25.58M | 22.74M | 22.15M | 21.20M | 19.50M | 20.32M |
| Net Income | 6.32M | 4.13M | 4.58M | 3.61M | 5.06M | 7.18M | 1.88M | (15,000) | (492,000) | 114,000 | (959,000) | (2.19M) |
| EPS | 0.08 | 0.05 | 0.06 | 0.05 | 0.07 | 0.09 | 0.02 | -0.00 | -0.01 | 0.00 | -0.01 | -0.03 |
| Free Cash Flow | (1.25M) | 578,000 | 3.67M | 1.11M | 7.85M | 8.51M | 3.45M | (276,000) | 254,000 | 628,000 | 370,000 | 3.27M |
| FCF / Share | -0.02 | 0.01 | 0.04 | 0.01 | 0.10 | 0.11 | 0.04 | -0.00 | 0.00 | 0.01 | 0.00 | 0.04 |
| Operating CF | (1.19M) | 679,000 | 3.69M | 1.25M | 7.88M | 8.58M | 3.50M | (264,000) | 295,000 | 649,000 | 396,000 | 3.28M |
| Total Assets | 114.33M | 106.41M | 98.14M | 91.53M | 81.34M | 68.28M | 56.52M | 54.03M | 54.08M | 54.96M | 53.48M | 53.17M |
| Total Debt | 2.58M | 2.82M | 3.06M | 3.29M | 3.52M | 2.65M | 2.90M | 3.12M | 3.23M | 3.28M | 3.79M | 3.94M |
| Cash & Equiv | 66.55M | 64.79M | 64.14M | 60.32M | 55.46M | 44.51M | 32.25M | 27.73M | 27.41M | 27.17M | 26.62M | 26.25M |
| Book Value | 82.33M | 76.53M | 70.68M | 64.19M | 55.34M | 46.09M | 34.37M | 30.72M | 28.95M | 28.46M | 27.31M | 27.15M |
| Return on Equity | 0.08 | 0.05 | 0.06 | 0.06 | 0.09 | 0.16 | 0.05 | -0.00 | -0.02 | 0.00 | -0.04 | -0.08 |
NAGE News
Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026
Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026
Niagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseases
Implied Volatility Surging for Niagen Bioscience Stock Options
Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference
Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science
Niagen Bioscience Announces Participation in Upcoming Investor Conferences
Niagen Bioscience (NAGE) Q1 Earnings and Revenues Top Estimates
Niagen Bioscience, Inc. (NAGE) Q1 2026 Earnings Call Transcript
Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results